SANTA CLARA (dpa-AFX) - Agilent Technologies Inc. (A), a life sciences, diagnostics and applied chemical company, announced Thursday that it has signed a deal with Chinese diagnostics company Burning Rock. Under the agreement, Burning Rock will develop cancer diagnostics in China based on the Agilent SureSelect target enrichment system.
Agilent provides target enrichment for next-generation DNA sequencing. Burning Rock is a fast-growing company focused on developing cancer diagnostics based on DNA sequencing.
Yusheng Han, the founder and chief executive officer of Burning Rock, said, 'Collaboration between our two companies will provide additional high-quality molecular diagnostic solutions based on next-generation sequencing, including non-invasive testing, relapse monitoring, early-stage diagnosis and cancer susceptibility.'
Burning Rock plans to register its molecular diagnostic kit with the China Food and Drug Administration. The company believes the kit could become the first CFDA-approved capture sequencing-based cancer diagnostic assay in the Chinese market.
Copyright RTT News/dpa-AFX